Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Fallopian Tube Neoplasms × pertuzumab × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 10 Neoplasms 4 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 HER2-positive Breast Cancer 2 Triple Negative Breast Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Malignant Solid Neoplasm 1 Hemangiosarcoma 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Early Breast Cancer 1 Endometrial Neoplasms 1 Brain Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

olaparib 12 Bevacizumab 12 Carboplatin 11 Paclitaxel 10 Specimen Handling 9 Magnetic Resonance Spectroscopy 9 liposomal doxorubicin 5 Taxes 5 Gemcitabine 5 Biopsy 5 cediranib 4 Doxorubicin 4 pembrolizumab 3 niraparib 3 Immunoglobulin G 3 Drug Therapy 3 Disulfides 3 mirvetuximab soravtansine 2 adavosertib 2 Platinum 2 Docetaxel 2 Cisplatin 2 130-nm albumin-bound paclitaxel 2 tremelimumab 1 trastuzumab deruxtecan 1 taxane 1 talazoparib 1 sotorasib 1 rucaparib 1 pelcitoclax 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡